Theriva Biologics
TOVX
22 hedge funds and large institutions have $385K invested in Theriva Biologics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
41% more capital invested
Capital invested by funds: $272K → $385K (+$113K)
5% more funds holding
Funds holding: 21 → 22 (+1)
1.46% more ownership
Funds ownership: 2.82% → 4.28% (+1.5%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$49.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$46.9K |
| 3 |
Jane Street
New York
|
+$34.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12.3K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$34.8K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$8.78K |
| 3 |
Barclays
London,
United Kingdom
|
-$6.85K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$6.54K |
| 5 |
Two Sigma Investments
New York
|
-$5.3K |
TOVX Hedge Fund Activity: Q1 2026 in Review
22 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2026, worth a combined $385K — up 41% from $272K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TOVX positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $49.9K. The largest seller was Morgan Stanley, cutting an estimated $34.8K.
- 22 institutional investors held Theriva Biologics (TOVX) as of Q1 2026, up from 21 in Q4 2025.
- Funds reported $385K of Theriva Biologics stock for Q1 2026, up 41% quarter-over-quarter.
- 5 funds opened new Theriva Biologics positions in Q1 2026 and 3 closed out, a net change of +2 holders.
- The largest Theriva Biologics buyer in Q1 2026 was Virtu Financial, an estimated $49.9K added.
- The largest Theriva Biologics seller in Q1 2026 was Morgan Stanley, an estimated $34.8K sold.
Based on aggregated 13F filings for Q1 2026.